# | Title | Journal | Year | Citations |
---|
|
1 | Lung cancer: current therapies and new targeted treatments | Lancet, The | 2017 | 2,436 |
2 | PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project | Journal of Thoracic Oncology | 2017 | 1,100 |
3 | Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer | Journal of Thoracic Oncology | 2012 | 599 |
4 | Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas | Journal of Clinical Oncology | 2006 | 538 |
5 | Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients | Journal of Clinical Oncology | 2009 | 535 |
6 | New and emerging targeted treatments in advanced non-small-cell lung cancer | Lancet, The | 2016 | 396 |
7 | IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients | Journal of Clinical Oncology | 2005 | 368 |
8 | PD-L1 Expression in Lung Cancer | Journal of Thoracic Oncology | 2016 | 366 |
9 | Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. | Journal of Clinical Investigation | 1997 | 293 |
10 | High-Throughput Tissue Microarray Analysis Used to Evaluate Biology and Prognostic Significance of the E-Cadherin Pathway in Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2002 | 264 |
11 | Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer | Cancer Immunology Research | 2019 | 237 |
12 | The E-cadherin cell–cell adhesion complex and lung cancer invasion, metastasis, and prognosis | Lung Cancer | 2002 | 215 |
13 | Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer | Cancer Discovery | 2013 | 204 |
14 | Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies | Lung Cancer | 2003 | 189 |
15 | Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies | European Journal of Cancer | 2013 | 153 |
16 | HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors | Clinical Cancer Research | 2009 | 151 |
17 | Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer | Oncotarget | 2015 | 147 |
18 | Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer | Journal of Clinical Endocrinology and Metabolism | 2016 | 145 |
19 | Tumor-Associated Lymphocytes and Increased FoxP3+ Regulatory T Cell Frequency Correlate with More Aggressive Papillary Thyroid Cancer | Journal of Clinical Endocrinology and Metabolism | 2010 | 138 |
20 | Characteristics of Lung Cancers Harboring NRAS Mutations | Clinical Cancer Research | 2013 | 135 |
21 | Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma | Melanoma Research | 2017 | 125 |
22 | Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? | Archives of Pathology and Laboratory Medicine | 2016 | 119 |
23 | Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012 | Journal of Thoracic Oncology | 2013 | 115 |
24 | Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue | Molecular Carcinogenesis | 2006 | 113 |
25 | Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer | British Journal of Cancer | 2012 | 110 |
26 | Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society | Archives of Pathology and Laboratory Medicine | 2016 | 107 |
27 | Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society | Archives of Pathology and Laboratory Medicine | 2016 | 100 |
28 | Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4–anaplastic lymphoma kinase gene fusion | Blood | 2001 | 99 |
29 | Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer | Molecular Cancer | 2014 | 96 |
30 | The DNA-Bending Protein HMG-1 Enhances Progesterone Receptor Binding to Its Target DNA Sequences | Molecular and Cellular Biology | 1994 | 94 |
31 | Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib | Annals of Oncology | 2006 | 93 |
32 | HER2/neu expression in malignant lung tumors | Seminars in Oncology | 2002 | 92 |
33 | Long-Term Dietary Habits Affect Soy Isoflavone Metabolism and Accumulation in Prostatic Fluid in Caucasian Men | Journal of Nutrition | 2005 | 88 |
34 | PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer | Cancer Immunology Research | 2015 | 88 |
35 | EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) | Journal of Thoracic Oncology | 2007 | 86 |
36 | Genetic Abnormalities of the EGFR Pathway in African American Patients With Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2009 | 86 |
37 | Population-Based Estimate of the Contribution of TP53 Mutations to Subgroups of Early-Onset Breast Cancer: Australian Breast Cancer Family Study | Cancer Research | 2010 | 86 |
38 | Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas | Cancer Prevention Research | 2008 | 84 |
39 | The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer | Cancer | 2014 | 84 |
40 | Acquisition of p16INK4Aandp15INK4BGene Abnormalities Between Initial Diagnosis and Relapse in Children With Acute Lymphoblastic Leukemia | Blood | 1999 | 82 |
41 | Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer | Cellular Oncology (Dordrecht) | 2013 | 80 |
42 | The Insulin-Like Growth Factor Pathway in Lung Cancer | Journal of Thoracic Oncology | 2008 | 78 |
43 | Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis | Clinical Cancer Research | 2011 | 75 |
44 | HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients | British Journal of Cancer | 2005 | 73 |
45 | Epidermal growth factor receptor immunohistochemistry | Cancer | 2008 | 70 |
46 | Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer | Cancer | 2013 | 69 |
47 | Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society | Archives of Pathology and Laboratory Medicine | 2016 | 68 |
48 | Canine sarcomas as a surrogate for the human disease | | 2018 | 63 |
49 | Leveraging the immune system to treat advanced thyroid cancers | Lancet Diabetes and Endocrinology,the | 2017 | 62 |
50 | Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer | Current Opinion in Oncology | 2005 | 60 |